Cancer & Autism Drug Therapeutics Drug Developer
Location United States
Asking Price Range $2.5M - $5.0M
Gross Revenues $0
Net Profit / Cash Flow $0
Cash Flow Type EBITDA
Seller Finance Not Disclosed
Year Established 2004
Number of Employees 6 - 9
Relocatable Not Disclosed
Number of Employees 6 - 9
Real Estate Leased
Description Cancer & Autism Therapeutic Drug developer is seeking partner(s) who are capable of bringing from $ 5 million up to $25 million to be used for IND enabling studies. So far the company has spent jointly with the major U.S. University that has developed this technology in excess of $26 million.
SIGNIFICANT DEVELOPMENT: The company discovered a few months ago that its technology is also applicable to treating a broad spectrum of canine animal cancers. The significant implication of this discovery is that it will enable the company's Veterinary Products division to take products to the market within about 2 years or sooner by taking advantage of provision of the MUMS (Minor Use Minor Species) Act of 2004. It is worth noting that potential partners who are interested in affiliating themselves to the Veterinary Products division they may do so.
TECHNOLOGY HIGHLIGHTS: In essence company's technology may be summarized as follows: Small Molecule Drugs (S.M.D.'s) can block/slow-down the production of specific proteins that are critical for cancer growth and survival. The use of such S.M.D.'s may either kill cancer cells to improve efficacy and/or transform a fatal disease to a chronic illness with an acceptable quality of life and extended survival. The company's lead drug candidates are inhibitors of mRNA translation at the level of initiation, and abrogate growth of human cancer cell lines and xenografted human tumors in mice with high potency and minimal or no toxicity. It is also worth noting that human cancer zenographic studies using two of the company's lead S.M.D.'s tested against breast cancer and melanoma, demonstrated 100% tumor inhibition and 20% to 30% tumor reduction.
DISCLAIMERS:
Business Broker is neither a Broker-Dealer nor a registered Investment Adviser. Where applicable, securities transactions are conducted by broker-dealer.
Prospective Partners are expected to conduct their own independent due diligence.
Click Here To Contact Seller
For more opportunities like this go to:
|
NEWSLETTER
|
Sign up for Free Industry-Related News on Business and Franchise Opportunities
|
|